Cargando…

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic

INTRODUCTION: This was a sub-group analysis of patients with uncontrolled persistent allergic asthma (AA) in the healthcare setting of the Czech Republic, from a global non-interventional, 2-year post-marketing, observational eXpeRience registry. AIM: To evaluate the real-life effectiveness and safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirchnerová, Olga Růžičková, Valena, Tomáš, Novosad, Jakub, Teřl, Milan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409880/ https://www.ncbi.nlm.nih.gov/pubmed/30858777 http://dx.doi.org/10.5114/ada.2018.76606

Ejemplares similares

Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry
por: Vaník, Petr, et al.
Publicado: (2020)

Serum periostin levels in asthma patients in relation to omalizumab therapy and presence of chronic rhinosinusitis with nasal polyps
por: Novosad, Jakub, et al.
Publicado: (2020)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry
por: Hutyrová, Beáta, et al.
Publicado: (2018)

The “real-world” effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study
por: Siracká, Simona, et al.
Publicado: (2022)

Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
por: Barnes, Neil, et al.
Publicado: (2013)

Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland
por: Sztafińska, Anna, et al.
Publicado: (2021)

Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia
por: Růžičková, Olga, et al.
Publicado: (2018)

Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2013)

Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2014)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
por: Lee, Jason K, et al.
Publicado: (2020)

The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study
por: Bhutani, Mohit, et al.
Publicado: (2017)

Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study
por: Al Ahmad, Mona, et al.
Publicado: (2022)

Hantaviruses in the Czech Republic
por: Pejčoch, Milan, et al.
Publicado: (2003)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Corrigendum: Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study
por: Su, Nan, et al.
Publicado: (2023)

Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study
por: Wang, Wen, et al.
Publicado: (2023)

Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control
por: de Carvalho-Pinto, Regina Maria, et al.
Publicado: (2017)

Influence of the diagnosis chronic rhinosinusitis on asthma response to omalizumab in severe, uncontrolled asthmatics
por: Sintobin, Ina, et al.
Publicado: (2015)

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?
por: Novosad, Jakub, et al.
Publicado: (2020)

The dynamics of the manifestations of atopic dermatitis in severe persistent uncontrolled asthma children with omalizumab therapy
por: Vishneva, Elena, et al.
Publicado: (2015)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea
por: Lee, Ji-Ho, et al.
Publicado: (2018)

Molecular Epidemiology of Hantaviruses in the Czech Republic
por: Zelena, Hana, et al.
Publicado: (2019)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Tula Hantavirus Infection in Immunocompromised Host, Czech Republic
por: Zelená, Hana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cprejf3058ogjeftft0pdrjtgi